A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Status:
Recruiting

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Phase 1

Incyte Corporation

Cetuximab